Substance use disorders affect businesses in surprising ways. Although there are obvious signs that an employee
is struggling with a substance use disorder, there are other factors affecting their workplace performance that
may be less obvious. Unfortunately, a survey from the National Safety Council found that employers
underestimate how prescription drug abuse affects their businesses.
Employers may not realize some of the facts illuminated in the study, such as:
• Employees with substance use disorders miss nearly 50 percent more days than their peers and up to six
weeks of work annually.
• Healthcare costs for employees who misuse or abuse prescription drugs are three times the costs for an
average employee.
• Getting an employee into treatment can save an employer up to $2,607 per worker annually.
The survey serves as a reminder that although some employees need support, they may not ask for it.
“Businesses that do not address the prescription drug crisis are like ostriches sticking their head in the sand,”
said Deborah A.P. Hersman, president and CEO of the National Safety Council. “The problem exists and doing
nothing will harm your employees and your business.”
The National Safety Council alongside NORC at the University of Chicago and Shatterproof created a tool to
show how the substance use disorder crisis can affect your workplace. The Substance Use Cost Calculator is a
quick and easy way to track the potential cost of substance use disorders. Employers input basic statistics about
their workforce, such as industry, location, and number of employees. The tool then calculates the estimated
prevalence of substance use disorders among employees and dependents.
Once you have all that information on hand, you can figure out a way to prioritize helping those who are
struggling with a substance use disorder. If you are worried about addressing such a difficult problem,
remember that leaders ask how they can help others and utilize subject-matter resources.
The FDA recently voted in favor of pushing a new formulation of oxycodone hydrochloride for approval. The new OxyContin formula is more difficult to crush or dissolve which will hopefully make it harder to be used as a drug of abuse . The FDA recommended that Purdue Pharma's application for a new, resin-coated formulation should replace the original version, which has been on the market since 1996. Randall Flick, MD, an anesthesiologist at the Mayo Clinic who voted to recommend approval of the drug said, "Clearly the old formulation is worse than the new, although I think the difference is relatively small," Flick concluded, "Hardcore abusers are likely to devise new ways to break down the harder tablet or figure out which solvents will dissolve it fastest, within 'day or weeks' of the product's release on the market."